Oncology

Latest News

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Gen Li, PhD, MBA, president and founder of Phesi
Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Ovarian Cancer: Coverage of PARP Inhibitors
November 28th 2017

Ovarian Cancer: Coverage of PARP Inhibitors

Consulting With Gynecologic Oncologists for Input
November 28th 2017

Consulting With Gynecologic Oncologists for Input

Guidance for Payer Decisions in Ovarian Cancer
November 28th 2017

Guidance for Payer Decisions in Ovarian Cancer

Management Challenges in Ovarian Cancer
November 28th 2017

Management Challenges in Ovarian Cancer

Patient Selection and PARP Inhibitors in Ovarian Cancer
November 28th 2017

Patient Selection and PARP Inhibitors in Ovarian Cancer

Predictive Markers in Ovarian Cancer
November 28th 2017

Predictive Markers in Ovarian Cancer

Ovarian Cancer: Practical Considerations in Maintenance
November 28th 2017

Ovarian Cancer: Practical Considerations in Maintenance

Efficacy and Safety of Rucaparib: A Focus on ARIEL3
November 28th 2017

Efficacy and Safety of Rucaparib: A Focus on ARIEL3

Efficacy and Safety of Olaparib and Niraparib in Switch Maintenance
November 28th 2017

Efficacy and Safety of Olaparib and Niraparib in Switch Maintenance

Delaying Recurrence in Ovarian Cancer
November 28th 2017

Delaying Recurrence in Ovarian Cancer

Role of PARP Inhibition in Ovarian Cancer
November 28th 2017

Role of PARP Inhibition in Ovarian Cancer

Expertise on the Ovarian Cancer Healthcare Team
November 28th 2017

Expertise on the Ovarian Cancer Healthcare Team

Understanding Ovarian Cancer
November 28th 2017

Understanding Ovarian Cancer

Substantial Proportion of Patients Diagnosed With Incident Cancer Have Survived a Prior Cancer
November 28th 2017

Substantial Proportion of Patients Diagnosed With Incident Cancer Have Survived a Prior Cancer

Jaime Rosenberg
A study published in JAMA Oncology found that a significant number of patients newly diagnosed with cancer have had a prior cancer. The prevalence differed among age group and incident cancer type.
Podcast: This Week in Managed Care—CMS Addresses Drug Costs, and Other Health News
November 25th 2017

Podcast: This Week in Managed Care—CMS Addresses Drug Costs, and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: November 24, 2017
November 24th 2017

This Week in Managed Care: November 24, 2017

This week, the top managed care stories included a new rule from CMS to address drug costs for seniors; a campaign to get payers to fund the artificial pancreas is working; and a new survey identifies how Americans prefer to treat pain.
Roche Sues Pfizer to Block Its Biosimilar Referencing Herceptin
November 23rd 2017

Roche Sues Pfizer to Block Its Biosimilar Referencing Herceptin

Jaime Rosenberg
Roche is suing Pfizer to block the company from selling a biosimilar referencing its breast-cancer drug Herceptin in the United States, claiming that the biosimilar infringes on 40 of its patents.
Chemotherapy, Radiation Therapy Recommended First for Certain Prostate Cancers, Lymphomas
November 22nd 2017

Chemotherapy, Radiation Therapy Recommended First for Certain Prostate Cancers, Lymphomas

Laura Joszt, MA
Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine.
Site Logo
November 21st 2017

Analysis Identifies Attributes That Likely Contribute to High-Value Oncology Care

Jaime Rosenberg
An analysis using mixed quantitative and qualitative methods, as well as site visits to 7 US oncology practices, identified 13 attributes within 5 themes that potentially contribute to high-quality care at a relatively low total cost.
Site Logo
November 18th 2017

Navigators Offer Touch Points on Patients' Cancer Journey

Mary Caffrey
The evolution of the navigator role has been an important development in cancer care, according to panelists who offered various perspectives on helping patients along the cancer journey.
Site Logo
November 18th 2017

NQF and CAPC Team Up to Set Quality Standards for Community-Based Serious Illness Care

Jaime Rosenberg
With the growing shift to community-based and patient-centered care, the National Quality Forum (NQF) and the Center to Advance Palliative Care (CAPC) have launched initiatives to ensure that patients with serious illness receive safe, effective, and high-quality care. At the same time, professionals in the healthcare industry are highlighting the importance of integrating this type of care into the oncology practice.
ASCO's TAPUR Study Expands to Enroll Patients Receiving Immunotherapy
November 17th 2017

ASCO's TAPUR Study Expands to Enroll Patients Receiving Immunotherapy

AJMC Staff
With an expansion that includes immunotherapy combination treatments, the American Society of Clinical Oncology (ASCO)’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study has now grown to 500 participants and 16 therapies.
Site Logo
November 17th 2017

Oncologists Can Save Oncology If They Take Ownership of Costs, Kolodziej Says

Mary Caffrey
High chemotherapy costs are only one reason for the rising cost of cancer care. End-of-life care and hospitalizations are within an oncologist's control and must be better managed given new reimbursement structures.
Study Finds Oncology Care Is Cheaper in Community Settings Than Hospital-Based Practices
November 17th 2017

Study Finds Oncology Care Is Cheaper in Community Settings Than Hospital-Based Practices

Jaime Rosenberg
Authors of the study found that the mean total, chemotherapy, and physician costs were all lower in community settings compared with hospital-based settings for patients with breast, lung, and colorectal cancer. There were also fewer emergency department visits both 3 and 10 days following treatment.
FDA Action on MSK Tumor Profiling Assay Breaks Ground on Multiple Fronts
November 17th 2017

FDA Action on MSK Tumor Profiling Assay Breaks Ground on Multiple Fronts

Mary Caffrey
FDA on Thursday authorized a faster approval path for a next-generation sequencing assay developed at Memorial Sloan Kettering Cancer Center (MSK) that represents both a scientific and regulatory breakthrough at the agency.
Predicting Which Patients Will Benefit From Immunotherapy
November 16th 2017

Predicting Which Patients Will Benefit From Immunotherapy

AJMC Staff
A mathematical model may help providers better understand which patients will benefit from certain immunotherapy.
Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors
November 15th 2017

Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors

AJMC Staff
Cyclin-dependent kinase 4/6 inhibitors may have proven benefits for treating metastatic breast cancer, but the therapies are associated with hematological toxicities and febrile neutropenia.
Dr Amy Abernethy on Improving Patient Access to Oncology Clinical Trials
November 14th 2017

Dr Amy Abernethy on Improving Patient Access to Oncology Clinical Trials

As oncology moves toward more deep diagnostic testing and as standard of care continues to quickly evolve, technology advancements are necessary to continue to improve patient access to clinical trials, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
Do Oral Parity Laws Reduce OOP Spending for Patients?
November 14th 2017

Do Oral Parity Laws Reduce OOP Spending for Patients?

Surabhi Dangi-Garimella, PhD
According to a new analysis by Stacy Dusetzina, PhD, and colleagues, state oral parity laws—devised to equate out-of-pocket (OOP) spending for patients, irrespective of whether their treatment is an oral agent or an infusion—are not consistent with reducing patient OOP costs for oral anticancer agents.
Site Logo
November 14th 2017

The Influence of Provider Characteristics and Market Forces on Response to Financial Incentives

Brock O&rsquo Neil, MD Mark Tyson, MD Amy J. Graves, SM, MPH Daniel A. Barocas, MD, MPH Sam S. Chang, MD, MBA David F. Penson, MD, MPH Matthew J. Resnick, MD, MPH
We determine a specialist physician phenotype responsive to financial incentives that may be leveraged to identify physicians and markets well-suited for participation in alternative payment models.
<1
...
636465666768697071
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo